Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Ear Neoplasms × Clear all

Phase

Status

Withdrawn 1 Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 403 Neoplasms 276 Carcinoma, Non-Small-Cell Lung 226 Prostatic Neoplasms 213 Lung Neoplasms 147 Colorectal Neoplasms 145 Pancreatic Neoplasms 130 Leukemia, Myeloid, Acute 128 Neoplasm Metastasis 122 Carcinoma, Hepatocellular 115 Multiple Myeloma 114 Lymphoma 114 Ovarian Neoplasms 95 Melanoma 95 Head and Neck Neoplasms 94 Brain Neoplasms 89 Leukemia 86 Recurrence 83 Leukemia, Lymphocytic, Chronic, B-Cell 83 Glioblastoma 76 Precursor Cell Lymphoblastic Leukemia-Lymphoma 75 Lymphoma, Non-Hodgkin 74 Colonic Neoplasms 74 Squamous Cell Carcinoma of Head and Neck 69 Lymphoma, Follicular 66 Lymphoma, Large B-Cell, Diffuse 64 Carcinoma, Renal Cell 62 Hematologic Neoplasms 61 Rectal Neoplasms 55 Stomach Neoplasms 52

Interventions

Saline Solution 1 Ringer's Lactate 1 Ofloxacin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00584155 2015-05-27

Protection From Cisplatin Ototoxicity by Lactated Ringers

University of Oklahoma

Phase 1 Withdrawn

Ear Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon ⚡